Nat Commun:基于钼的纳米晶簇能够作为抗氧化物减轻急性肾脏损伤

2018-12-31 AlexYang MedSci原创

急性肾损伤(AKI)是一种常见的与活性氧(ROS)相关的肾脏疾病,每年都能够引起巨大的死亡人数,然而,该疾病的支持性治疗只有在诊所中才可以进行。能够具有在肾脏中高速积累的抗氧化物的开发是迫切需要的,从而来帮助组织AKI。最近,有研究人员报道了基于钼的多金属氧酸盐(POM)纳米晶簇且肾脏优势吸收作为一种新的保护肾脏的纳米抗氧化药物。这些POM纳米晶簇含有钼离子不稳定的可变的价态,具有清除有害的ROS

急性肾损伤(AKI)是一种常见的与活性氧(ROS)相关的肾脏疾病,每年都能够引起巨大的死亡人数,然而,该疾病的支持性治疗只有在诊所中才可以进行。能够具有在肾脏中高速积累的抗氧化物的开发是迫切需要的,从而来帮助阻止AKI。

最近,有研究人员报道了基于钼的多金属氧酸盐(POM)纳米晶簇且肾脏优势吸收作为一种新的保护肾脏的纳米抗氧化药物。这些POM纳米晶簇含有钼离子不稳定的可变的价态,具有清除有害的ROS的能力。他们的结果阐释了POM纳米晶簇能够有效减轻AKI在小鼠中的临床症状,并且与肾脏中动态PET成像、血清测试、肾脏组织染色和生物标记检测结果一致。

最后,研究人员指出,POM纳米晶簇对活体动物AKI的治疗性作用表明了POM纳米晶簇在AKI患者治疗中是有应用价值的,同时也包括了其他ROS相关的疾病。

原始出处:

Dalong Ni, Dawei Jiang, Christopher J. Kutyreff et al. Molybdenum-based nanoclusters act as antioxidants and ameliorate acute kidney injury in mice. Nat Commun. 21 Dec 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1883504, encodeId=9e1318835041e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Sep 03 16:47:00 CST 2019, time=2019-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087490, encodeId=026d208e49021, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Jul 18 13:47:00 CST 2019, time=2019-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397686, encodeId=0950139e68633, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Wed Jan 02 01:47:00 CST 2019, time=2019-01-02, status=1, ipAttribution=)]
    2019-09-03 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1883504, encodeId=9e1318835041e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Sep 03 16:47:00 CST 2019, time=2019-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087490, encodeId=026d208e49021, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Jul 18 13:47:00 CST 2019, time=2019-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397686, encodeId=0950139e68633, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Wed Jan 02 01:47:00 CST 2019, time=2019-01-02, status=1, ipAttribution=)]
    2019-07-18 liuli5079
  3. [GetPortalCommentsPageByObjectIdResponse(id=1883504, encodeId=9e1318835041e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Sep 03 16:47:00 CST 2019, time=2019-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087490, encodeId=026d208e49021, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Thu Jul 18 13:47:00 CST 2019, time=2019-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1397686, encodeId=0950139e68633, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoNX3lUOlDKGBUEPNwZx0nibmdcFyeibnX4WMhUSCU2REpGRWtSmnT2CCs0dA5waxvJknYDxwtYnIcQ/132, createdBy=294e2500218, createdName=ms3046638856685384, createdTime=Wed Jan 02 01:47:00 CST 2019, time=2019-01-02, status=1, ipAttribution=)]

相关资讯

NEJM:急性肾损伤合并脓毒症患者肾脏替代治疗的时机选择

由此可见,在患有严重急性肾损伤的感染性休克患者中,在接受肾脏替代治疗开始的早期策略的患者与分配至延迟策略的患者之间90天总体死亡率没有显著差异。

Circ: Cardiovascular Interventions:动脉粥样硬化的程度可以预测TAVR后急性肾损伤的发生、严重程度和恢复

肾上腺动脉粥样硬化负荷与TAVR后AKI的发生、严重程度和恢复相关。

JAMA Intern Med:急性肾损伤患者服药降压药物可改善预后

研究认为,急性肾损伤患者院外服用血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂可降低死亡率,但导致肾病住院风险增加,建议患者在服药同时对肾功能进行持续监测

KIDNEY INT:急性肾损伤后不良结局的长期风险

由此可见,这些结果确定了AKI的不良长期结局,同时强调了损伤严重程度和临床状况在风险评估中的重要性。

急性肾损伤早诊,靠生物标志物来助力

急性肾损伤(AKI)是导致病人死亡的重要原因,AKI的人群发病率为2100/百万人群。需要肾脏替代治疗的AKI死亡率高达50%~80%,全球每年约有两百万人死于AKI。危重症患者,尤其是老年人近年AKI的发生率日益增加,已成为全球广泛关注的问题。多个在动物试验提示有效的AKI治疗药物在人类AKI均被证实无效,主要原因在于无法早期诊断AKI,错过了最佳的治疗“时间窗”。

A1M Pharma的候选药物ROSgard临床前研究显示出对急性肾损伤的强大保护作用

A1M Pharma宣布,该公司的候选药物ROSgard在美国与印第安纳大学合作进行的临床前研究中显示出对急性肾损伤(AKI)的强大保护作用。该公司为ROSgard在急性肾损伤领域的持续发展奠定了越来越坚实的基础。I期研究计划于2018年晚些时候开始,主要目的是评估候选药物的安全性。